<DOC>
	<DOCNO>NCT00002702</DOCNO>
	<brief_summary>RATIONALE : Interleukin-2 may stimulate person 's white blood cell kill cancer cell mouth oropharynx . Radiation therapy use high-energy x-rays damage tumor cell . It know whether give interleukin-2 surgery radiation therapy effective surgery radiation therapy alone . PURPOSE : This randomized phase III trial study surgery radiation therapy alone see well work compare surgery , radiation therapy , interleukin-2 treating patient cancer mouth oropharynx .</brief_summary>
	<brief_title>Surgery Radiation Therapy With Without Interleukin-2 Treating Patients With Cancer Mouth Oropharynx</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free overall survival patient previously untreated squamous cell carcinoma oral cavity oropharynx treat resection without neoadjuvant adjuvant perilymphatic interleukin-2 ( IL-2 ) radiotherapy . - Compare response rate patient treat regimen . - Determine local systemic effect locoregional IL-2 host-tumor interaction immune property patient . OUTLINE : This randomize , multicenter study . Patients stratify accord center tumor stage ( T2 , N0-2 v T2 , N3 T3-4 , N0-3 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo induction comprise interleukin-2 ( IL-2 ) via perilymphatic injection ipsilateral myelohyoid muscle insertion sternocleidomastoid muscle day 1-5 8-12 . Within 10 day last IL-2 injection , patient undergo en bloc resection primary tumor correspond lymphatic drainage area pre-study margin . Beginning within 4 week surgery , patient T2 , N0-3 disease pathohistological evidence node invasion capsular rupture node metastasis T3-4 , N0-3 disease undergo adjuvant radiotherapy 5 day week 4.5-6.5 week . Beginning within 4 week surgery radiotherapy ( applicable ) , patient receive adjuvant IL-2 via perilymphatic injection contralateral myelohyoid muscle insertion sternocleidomastoid muscle day 1-5 . Adjuvant IL-2 continue monthly least 1 year absence disease progression . - Arm II : Patients undergo resection radiotherapy ( eligible ) arm I . Patients follow monthly 1 year every 2 month 2 year . PROJECTED ACCRUAL : A total 260 patient ( 130 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma oral cavity oropharynx Operable , primary , unilateral , stage T24 , N03 , M0 disease No high probability bilateral lymphatic spread ( requirement bilateral neck dissection ) No tumor involvement follow site : Pterygopalatine fossa Carotid artery Maxillary sinus Facial skin Anterior floor mouth Base tongue infiltrate 1 cm Measurable evaluable disease physical exam and/or noninvasive imaging PATIENT CHARACTERISTICS : Age : 75 Performance status : ECOG 02 OR Karnofsky 70100 % Life expectancy : More 3 month Hematopoietic : WBC least 4,000/mm3 Platelet count least 60,000/mm3 Hematocrit least 30 % Hepatic : Bilirubin normal Hepatitis B surface antigen negative Renal : Creatinine normal Cardiovascular : No congestive heart failure No uncontrolled hypertension No coronary artery disease No serious arrhythmia No evidence prior myocardial infarction ECG ( stress test require doubt ) Other : HIV negative No autoimmune disease No contraindication pressor agent No serious infection require antibiotic No concurrent primary malignancy Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No prior concurrent immunotherapy Chemotherapy : No prior concurrent chemotherapy Endocrine therapy : No prior concurrent hormonal therapy No concurrent corticosteroid Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics No prior major organ allograft Other : No prior therapy No concurrent investigational drug , agent , device No concurrent nonsteroidal antiinflammatory drug , ranitidine , cimetidine , coumarin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>tongue cancer</keyword>
</DOC>